Skip to main content
Top
Published in: Advances in Therapy 1/2021

01-01-2021 | Commentary

Caregivers’ and Physicians’ Perspectives on Alpha-Mannosidosis: A Report from Italy

Authors: Elena Verrecchia, Ludovico L. Sicignano, Maria Grazia Massaro, Rossana Rocco, Gabriella Silvestri, Silvia Rossi, Raffaele Manna

Published in: Advances in Therapy | Issue 1/2021

Login to get access

Abstract

Alpha-mannosidosis is a rare lysosomal storage disorder that generally presents in early childhood. It is a progressive, highly heterogeneous disease that is difficult to recognize, and a diagnosis is usually reached after referrals to multiple specialists. It is important to understand the challenges faced by patients and their caregiver up to and after a diagnosis of alpha-mannosidosis. In this report, we describe the process of alpha-mannosidosis diagnosis and treatment from the caregivers’ and physicians’ perspectives. For the caregivers’ perspective, the mothers of two patients with alpha-mannosidosis (‘Adele’ aged 35 years and ‘Amedeo’ aged 40 years) were interviewed in their homes in Italy, and anonymized transcripts were used to describe their experiences. Adele lived in a large city with access to hospitals and specialized centers and was diagnosed with alpha-mannosidosis before 3 years of age. Amedeo was from a small village and was diagnosed when he was 10–11 years old. In both cases, their mothers sought help from pediatricians and other specialists for recurrent infections and delayed speech and motor development in the first years of their lives, but diagnosis was delayed. Although the diagnostic pathway was concerning and frustrating for her mother, Adele was able to live at home and receive multidisciplinary care and psychosocial support locally, but the transition from pediatric to adult services was difficult. She is currently waiting for access to enzyme replacement therapy. Amedeo had to travel widely and frequently to receive a diagnosis and access supportive treatment. The cumulative morbidity resulting from the delays and poor access to care necessitated long-term residential care. From the physicians’ perspective, greater awareness of alpha-mannosidosis is required among healthcare professionals and more support is needed for patients and caregivers, particularly those living in rural areas or small centers.
Literature
1.
go back to reference Malm D, Nilssen Ø. Alpha-mannosidosis. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, editors. GeneReviews®. Seattle (WA): University of Washington; 2001. Malm D, Nilssen Ø. Alpha-mannosidosis. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, editors. GeneReviews®. Seattle (WA): University of Washington; 2001.
2.
3.
go back to reference Adam J, Malone R, Lloyd S, Lee J, Hendriksz CJ, Ramaswami U. Disease progression of alpha-mannosidosis and impact on patients and carers—a UK natural history survey. Mol Genet Metab Rep. 2019;20:100480.CrossRef Adam J, Malone R, Lloyd S, Lee J, Hendriksz CJ, Ramaswami U. Disease progression of alpha-mannosidosis and impact on patients and carers—a UK natural history survey. Mol Genet Metab Rep. 2019;20:100480.CrossRef
4.
go back to reference Beck M, Olsen KJ, Wraith JE, et al. Natural history of alpha mannosidosis a longitudinal study. Orphanet J Rare Dis. 2013;8:88.CrossRef Beck M, Olsen KJ, Wraith JE, et al. Natural history of alpha mannosidosis a longitudinal study. Orphanet J Rare Dis. 2013;8:88.CrossRef
5.
go back to reference Malm D, Riise Stensland HM, Edvardsen O, Nilssen O. The natural course and complications of alpha-mannosidosis—a retrospective and descriptive study. J Inherit Metab Dis. 2014;37(1):79–82.CrossRef Malm D, Riise Stensland HM, Edvardsen O, Nilssen O. The natural course and complications of alpha-mannosidosis—a retrospective and descriptive study. J Inherit Metab Dis. 2014;37(1):79–82.CrossRef
6.
go back to reference Finocchiaro D, Rastelletti I, De-Almeida J, Lloyd S, Gupta P. A systematic review of the epidemiology of alpha-mannosidosis [abstract PSY26]. Value Health. 2018;21:S249.CrossRef Finocchiaro D, Rastelletti I, De-Almeida J, Lloyd S, Gupta P. A systematic review of the epidemiology of alpha-mannosidosis [abstract PSY26]. Value Health. 2018;21:S249.CrossRef
7.
go back to reference Lehalle D, Colombo R, O’Grady M, et al. Hearing impairment as an early sign of alpha-mannosidosis in children with a mild phenotype: report of seven new cases. Am J Med Genet A. 2019;179(9):1756–63.CrossRef Lehalle D, Colombo R, O’Grady M, et al. Hearing impairment as an early sign of alpha-mannosidosis in children with a mild phenotype: report of seven new cases. Am J Med Genet A. 2019;179(9):1756–63.CrossRef
8.
go back to reference Wiesinger T, Schwarz M, Mechtler TP, Liebmann-Reindl S, Streubel B, Kasper DC. α-Mannosidosis—an underdiagnosed lysosomal storage disease in individuals with an “MPS-like” phenotype. Mol Genet Metab. 2020;130(2):149–52.CrossRef Wiesinger T, Schwarz M, Mechtler TP, Liebmann-Reindl S, Streubel B, Kasper DC. α-Mannosidosis—an underdiagnosed lysosomal storage disease in individuals with an “MPS-like” phenotype. Mol Genet Metab. 2020;130(2):149–52.CrossRef
9.
go back to reference Guffon N, Tylki-Szymanska A, Borgwardt L, et al. Recognition of alpha-mannosidosis in paediatric and adult patients: presentation of a diagnostic algorithm from an international working group. Mol Genet Metab. 2019;126(4):470–4.CrossRef Guffon N, Tylki-Szymanska A, Borgwardt L, et al. Recognition of alpha-mannosidosis in paediatric and adult patients: presentation of a diagnostic algorithm from an international working group. Mol Genet Metab. 2019;126(4):470–4.CrossRef
10.
go back to reference Zielonka M, Garbade SF, Kolker S, Hoffmann GF, Ries M. Ultra-orphan lysosomal storage diseases: a cross-sectional quantitative analysis of the natural history of alpha-mannosidosis. J Inherit Metab Dis. 2019;42(5):975–83.CrossRef Zielonka M, Garbade SF, Kolker S, Hoffmann GF, Ries M. Ultra-orphan lysosomal storage diseases: a cross-sectional quantitative analysis of the natural history of alpha-mannosidosis. J Inherit Metab Dis. 2019;42(5):975–83.CrossRef
12.
go back to reference Harmatz P, Cattaneo F, Ardigo D, et al. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): novel global treatment response model and outcomes in patients with alpha-mannosidosis. Mol Genet Metab. 2018;124(2):152–60.CrossRef Harmatz P, Cattaneo F, Ardigo D, et al. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): novel global treatment response model and outcomes in patients with alpha-mannosidosis. Mol Genet Metab. 2018;124(2):152–60.CrossRef
13.
go back to reference Borgwardt L, Guffon N, Amraoui Y, et al. Efficacy and safety of velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. J Inherit Metab Dis. 2018;41(6):1215–23.CrossRef Borgwardt L, Guffon N, Amraoui Y, et al. Efficacy and safety of velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. J Inherit Metab Dis. 2018;41(6):1215–23.CrossRef
14.
go back to reference Borgwardt L, Lund A, Amraoui Y, et al. Long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) slows disease progression in adult patients suffering from alpha-mannosidosis [abstract 39]. Mol Genet Metab. 2017;120:S30.CrossRef Borgwardt L, Lund A, Amraoui Y, et al. Long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) slows disease progression in adult patients suffering from alpha-mannosidosis [abstract 39]. Mol Genet Metab. 2017;120:S30.CrossRef
15.
go back to reference Lund AM, Borgwardt L, Cattaneo F, et al. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. J Inherit Metab Dis. 2018;41(6):1225–33.CrossRef Lund AM, Borgwardt L, Cattaneo F, et al. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. J Inherit Metab Dis. 2018;41(6):1225–33.CrossRef
16.
go back to reference Phillips D, Hennermann JB, Tylki-Szymanska A, et al. Use of the Bruininks-Oseretsky test of motor proficiency (BOT-2) to assess efficacy of velmanase alfa as enzyme therapy for alpha-mannosidosis. Mol Genet Metab Rep. 2020;23:100586.CrossRef Phillips D, Hennermann JB, Tylki-Szymanska A, et al. Use of the Bruininks-Oseretsky test of motor proficiency (BOT-2) to assess efficacy of velmanase alfa as enzyme therapy for alpha-mannosidosis. Mol Genet Metab Rep. 2020;23:100586.CrossRef
17.
go back to reference Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterniary use and establishing a European Medicines Agency, Article 83 (2004). Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterniary use and establishing a European Medicines Agency, Article 83 (2004).
18.
go back to reference Gelb MH. Newborn screening for lysosomal storage diseases: methodologies, screen positive rates, normalization of datasets, second-tier tests, and post-analysis tools. Int J Neonatal Screen. 2018;4(3):23.CrossRef Gelb MH. Newborn screening for lysosomal storage diseases: methodologies, screen positive rates, normalization of datasets, second-tier tests, and post-analysis tools. Int J Neonatal Screen. 2018;4(3):23.CrossRef
19.
go back to reference Kumar AB, Hong X, Yi F, Wood T, Gelb MH. Tandem mass spectrometry-based multiplex assays for alpha-mannosidosis and fucosidosis. Mol Genet Metab. 2019;127(3):207–11.CrossRef Kumar AB, Hong X, Yi F, Wood T, Gelb MH. Tandem mass spectrometry-based multiplex assays for alpha-mannosidosis and fucosidosis. Mol Genet Metab. 2019;127(3):207–11.CrossRef
Metadata
Title
Caregivers’ and Physicians’ Perspectives on Alpha-Mannosidosis: A Report from Italy
Authors
Elena Verrecchia
Ludovico L. Sicignano
Maria Grazia Massaro
Rossana Rocco
Gabriella Silvestri
Silvia Rossi
Raffaele Manna
Publication date
01-01-2021
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 1/2021
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01574-w

Other articles of this Issue 1/2021

Advances in Therapy 1/2021 Go to the issue